Evidence map›Paper›PMID 37926534›Full record

ArticleInternal medicine (Tokyo, Japan)2024

De novo Hepatitis B Virus Reactivation during Treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Patient with Advanced Lung Cancer.

Ryota Horibe, Motohiro Yokota, Koujiro Uemura, Midori Hashimoto, Naoki Kawagishi, Kaoru Nishiyama

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryota HoribeDepartment of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan.
Motohiro YokotaDepartment of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan.
Koujiro UemuraDepartment of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan.
Midori HashimotoDepartment of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan.
Naoki KawagishiDepartment of Gastroenterology, NTT-East Corporation Sapporo Medical Center, Japan.
Kaoru NishiyamaDepartment of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 71-year-old woman was treated with osimertinib for stage IV adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Treatment led to improvements in the primary tumor, multiple lung metastases, and multiple bone metastases. However, nine months later, she presented with marked liver dysfunction and jaundice. Chest and abdominal computed tomography did not show abnormal findings in the liver parenchyma or biliary system. However, blood tests were positive for hepatitis B surface antigen and hepatitis B virus DNA, suggesting hepatitis B virus reactivation. The patient died of liver failure despite treatment with steroids and antiviral drugs.

Indexed as

AcrylamidesAniline CompoundsErbB ReceptorsHepatitis BHepatitis B virusLung NeoplasmsProtein Kinase InhibitorsVirus ActivationAdenocarcinomaAdenocarcinoma of LungAgedAntineoplastic AgentsFatal OutcomeFemaleHumansIndolesAcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesTyrosine Kinase InhibitorsEGFR-mutated lung adenocarcinomaEGFR-TKIHBV reactivation

Identifiers

PMID37926534
PMCPMC11239268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.